The dopamine biosynthesis and metabolism pathway is a critical neuronal pathway responsible for the production, packaging, and degradation of dopamine, a key catecholamine neurotransmitter. Dysregulation of this pathway is central to Parkinson's disease (PD) and contributes to various other neurodegenerative disorders including Alzheimer's disease (AD), Huntington's disease (HD), and multiple system atrophy (MSA)[@jankovic2023].
Dopamine is synthesized in catecholaminergic neurons primarily in the substantia nigra pars compacta (SNc), ventral tegmental area (VTA), and locus coeruleus. The pathway involves a series of enzymatic conversions starting from the essential amino acid phenylalanine, ultimately producing dopamine that is packaged into synaptic vesicles for neurotransmission[@bjorklund2019].
Phenylalanine hydroxylase (PAH) catalyzes the hydroxylation of the essential amino acid L-phenylalanine to L-tyrosine. This reaction requires: [@blau2010]
PAH is primarily expressed in the liver but is also present in catecholaminergic neurons where it provides the substrate for dopamine synthesis. Mutations in the PAH gene cause phenylketonuria (PKU), a disorder characterized by elevated phenylalanine levels that can impair dopamine synthesis if untreated[@furukawa2021].
Tyrosine hydroxylase (TH) is the rate-limiting enzyme in dopamine biosynthesis. It catalyzes the conversion of L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA) through hydroxylation of the tyrosine ring. This reaction: [@christine2018]
TH is expressed exclusively in catecholaminergic neurons and adrenal medulla. The TH gene is located on chromosome 11p15.5 and is a critical determinant of dopaminergic neuron survival. TH deficiency leads to Segawa syndrome, a dopamine-responsive dystonia[@youdim2006].
Aromatic L-amino acid decarboxylase (AADC, gene: DDC) catalyzes the decarboxylation of L-DOPA to dopamine. This enzyme: [@mannisto1999]
AADC deficiency is a rare neurodegenerative disorder causing severe motor dysfunction, seizures, and developmental delay. Gene therapy trials are currently targeting AADC delivery to the striatum as a treatment for Parkinson's disease[@lohr2017].
Monoamine oxidase (MAO) exists in two isoforms: [@beaulieu2011]
Both isoforms are located on the outer mitochondrial membrane. MAO-B activity increases with age, potentially contributing to increased oxidative stress in dopaminergic neurons. Selegiline and rasagiline are MAO-B inhibitors used in Parkinson's disease treatment[@vaughan2013].
COMT catalyzes the O-methylation of dopamine and its metabolites, primarily in the periphery but also in the brain[@kordower2013]:
VMAT2 (gene: SLC18A2) packages dopamine into synaptic vesicles[@dias2013]:
Dopamine acts through five G-protein coupled receptors (GPCRs) divided into two families[@park2018]:
| Family | Receptors | Signaling Pathway | Main Effects |
|---|---|---|---|
| D1-like | D1, D5 | Gs/olf → ↑cAMP | Motor facilitation, reward |
| D2-like | D2, D3, D4 | Gi/o → ↓cAMP | Motor inhibition, cognition |
D1 and D2 receptors are the most abundant in the basal ganglia. D2 receptor binding is reduced in Parkinson's disease, and this is used as a diagnostic marker in PET imaging[@stocchi2014].
DAT (gene: SLC6A3) is responsible for reuptake of dopamine from the synaptic cleft back into presynaptic terminals. This transporter: [@bankiewicz2010]
The dopamine biosynthesis pathway is central to PD pathogenesis[@mittermeyer2012]:
TH loss: TH-expressing neurons in the SNc are selectively vulnerable in PD. Post-mortem studies show 60-80% reduction in TH activity in the PD substantia nigra.
Oxidative stress: Dopamine autoxidation produces reactive oxygen species (ROS) including dopamine quinones and 6-hydroxydopamine (6-OHDA). The SNc has high iron levels, which catalyzes reactive oxygen species (ROS) formation.
Mitochondrial dysfunction: Complex I deficiency is well-documented in PD. Dopaminergic neurons have high energy demands for dopamine synthesis, packaging, and reuptake, making them particularly vulnerable to mitochondrial impairment.
Alpha-synuclein interaction: Alpha-synuclein aggregates can inhibit TH activity and dopamine vesicular packaging, creating a vicious cycle.
L-DOPA remains the gold standard for PD treatment[@kells2022]:
Several experimental approaches target the dopamine pathway[@olanow2009]:
AAV-TH + AAV-DDC: Adeno-associated virus delivery of TH and DDC genes to enhance endogenous dopamine synthesis.
AADC gene therapy: AAV-AADC (VY-AADC01) delivered to the striatum enhances conversion of L-DOPA to dopamine in phase I trials.
GDNF delivery: Glial cell line-derived neurotrophic factor supports dopaminergic neuron survival.
Additional evidence sources: [@yoritaka2021]